En un nuevo estudio, se ha identificado cerca de una veintena de genes que podrían contribuir a que algunas personas sean más susceptibles a la depresión, la ansiedad y rasgos como la irritabilidad o el neuroticismo. Estos genes estarían regulados por el gen RBFO …
Genes que promueven la depresión y otros trastornos psiquiátricos Read More »
Una investigación reciente ha revelado un intrigante orden oculto dentro de las imágenes rupestres de nueve cuevas de la zona de Euskal Herria. El estudio lo ha llevado a cabo Iñaki Intxaurbe, de la Universidad del País Vasco (EHU). Intxaurbe ha analizad …
Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
BMS picks Texas for new $2.3B manufacturing campus Read More »
The sector added 22,000 jobs in July, well below the monthly average of 36,000 new jobs added in the past year. Still, healthcare buoyed what was otherwise a weaker-than-expected report for the economy overall.
Acquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.
IRhythm grows heart monitoring leadership with $288M VitalConnect buy Read More »
The latest agreement includes higher fees for overseas firms, hiring transparency requirements and greater use of real-world evidence.
Device firms back latest MDUFA deal, while patients want more postmarket safety Read More »
NYU Langone Health and Dana-Farber Cancer Institute built an oncology decision support tool to guide clinicians through treatment. Now, the institutions are commercializing the product so other health systems can use it too.
When does it make sense to build software instead of buy? One health system’s answer. Read More »
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant Read More »
Definium Therapeutics’ closely watched anxiety readout could further validate its single-dose LSD candidate, while Compass Pathways advances a psilocybin program through a rolling FDA filing.
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts Read More »
Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline Read More »
